...
首页> 外文期刊>Current drug delivery >Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation.
【24h】

Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation.

机译:尼莫地平负载PLGA纳米颗粒:使用析因设计,表征和体外评估优化配方。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The present study was aimed at developing a sustained release formulation of Nimodipine (NIM) nanoparticles using the biodegradable polymers, poly (lactide-co-glycolide) (PLGA 50:50 and 85:15) as carrier. NIM is a widely used calcium channel blocker which has to be administered as an intravenous infusion for a prolonged period of 1-2 weeks in the treatment of cerebral vasospasm. A sustained release biodegradable formulation would serve to replace this conventional therapy of continuous intravenous administration. PLGA nanoparticles were prepared by a modified precipitation method using high pressure homogenizer at 10,000 to 14,000 psi. A 3(2) factorial design was applied for optimization of the formulation parameters and for studying the effect of two independent variables [drug: polymer ratio and concentration of surfactant (Pluronic F 127)] on entrapment efficiency and mean particle size (response variables). Contour plots were plotted which gave a visual representation of the two variables on the dependent variables and also indicated non-linear relationship between them. The nanoparticles had particle size of 131+/-1.9 nm for PLGA 50:50 and 196+/-2.2 nm for PLGA 85:15. Scanning Electron Microscopy studies indicated that nanoparticles had spherical shape with a regular surface. The nanoparticles had high entrapment efficiency (96.42+/-2.09% for PLGA 50:50 and 94.50+/-1.25% for PLGA 85:15). DSC thermograms indicated that NIM was dispersed as an amorphous state in the nanoparticles. In vitro drug release from the lyophilized nanoparticles showed 94.35 +/- 3.8% NIM release from PLGA (50:50) nanoparticles and 63.32 +/- 4.6% release from PLGA (85:15) nanoparticles in 25 days. The release was first ordered and fickian diffusion kinetics in both the cases. These preliminary results indicate that NIM loaded PLGA nanoparticles could be effective in sustaining its release for a prolonged period. However, further studies are needed to confirm its performance in vivo.
机译:本研究旨在开发使用生物可降解聚合物,聚丙交酯-乙交酯共聚物(PLGA 50:50和85:15)作为载体的尼莫地平(NIM)纳米颗粒的缓释制剂。 NIM是一种广泛使用的钙通道阻滞剂,在治疗脑血管痉挛时必须以静脉输注的形式持续1-2周。持续释放的可生物降解的制剂将代替连续静脉给药的这种常规疗法。 PLGA纳米粒子是通过改良的沉淀方法,使用高压均化器在10,000至14,000 psi下制备的。应用3(2)因子设计优化配方参数,并研究两个独立变量[药物:聚合物比和表面活性剂的浓度(Pluronic F 127)]对包封效率和平均粒径的影响(响应变量) 。绘制等高线图,以可视方式表示因变量上的两个变量,并指出它们之间的非线性关系。对于PLGA 50:50,纳米颗粒的粒径为131 +/- 1.9 nm,对于PLGA 85:15,纳米颗粒的粒径为196 +/- 2.2 nm。扫描电子显微镜研究表明,纳米颗粒具有规则表面的球形。纳米颗粒具有高的包封效率(对于PLGA 50:50为96.42 +/- 2.09%,对于PLGA 85:15为94.50 +/- 1.25%)。 DSC热谱图表明NIM以无定形状态分散在纳米颗粒中。从冻干的纳米粒子的体外药物释放显示在25天之内从PLGA(50:50)纳米粒子释放94.35 +/- 3.8%NIM,从PLGA(85:15)纳米粒子释放63.32 +/- 4.6%。在这两种情况下,释放都是有序的,并且是菲克扩散动力学。这些初步结果表明,负载NIM的PLGA纳米颗粒可以有效地延长其释放时间。但是,需要进一步的研究来确认其体内性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号